Menu
US
htrf-sting-variants-1920x400.jpg
Application Note

Unlock your STING polymorphism research with a comprehensive HTRF binding platform

STING protein is a mediator of innate immunity and a candidate for auto immune disease or cancer immunotherapy. Clinical trials are already ongoing, and targeting all STING variants has become crucial. R232 is the most common variant, and HAQ and H232 alleles are also present in the human population.

To help progress your research in identifying and charaterizing potential universal new STING therapeutics, Revvity has developed this note with:

  • How HTRF human and mouse STING assays are built up.
  • What their main features are.
  • How the most relevant and promising STING agonists, like ADU-S100, behave towards the different STING variants.

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

Unlock your STING polymorphism research with a comprehensive HTRF binding platform

Download Application Note